NewTimeSpace News: The CSRC has issued an overseas listing filing notice, pursuant to which Hunan Junxin Environmental Protection Co., Ltd. plans to issue no more than 221,434,400 overseas listed ordinary shares and list on the HKEX.
NewTimeSpace News: The CSRC has issued an overseas listing filing notice, pursuant to which Shenzhen Transsion Holdings Co., Ltd. plans to issue no more than 132,386,200 overseas listed ordinary shares and list on the HKEX; the Company is required to report the offering status within 15 business days after completion and to update filing materials if the offering is not completed within 12 months, with the notice serving only as confirmation of the filing information and not constituting a judgment on investment value.
NewTimeSpace News: On 13 August, Hunan Junxin Environmental Protection Co., Ltd. submitted a listing application to the Main Board of the Stock Exchange of Hong Kong, with CICC and CITIC SEC acting as joint sponsors. The Company has been listed on the ChiNext of the Shenzhen Stock Exchange since 2022 (301109.SZ).
NewTimeSpace News: On 13 August 2026, Hunan Junxin Environmental Protection Co., Ltd. （301109.SZ）submitted a listing application to the HKEX Main Board for the third time, with CICC and CITIC SEC as joint sponsors; as a provider of comprehensive waste treatment and resource utilization solutions, the Company operates the Changsha Environmental Protection Industrial Park, one of the largest environmental parks in China, ranks first in China by average grid electricity per tonne of waste incinerated in 2025, with aggregate daily incineration capacity of 10,600 tonnes and food waste treatment capacity of 1,200 tonnes per day.
NewTimeSpace News: Zaihui Inc.'s listing application filed with HKEX on 13 February 2026 has lapsed after six months; Haitong International acted as the original sole sponsor. The Company is China's largest provider of online operations and marketing solutions for the F&B industry, having served 43,890 clients cumulatively as of 30 September 2025, with market shares of 9.8% and 14.4% on Xiaohongshu and Dianping respectively and the fastest growth rate among China's top three new media solutions providers in 2024.
NewTimeSpace News: VivaVision Biotech (Zhejiang) Co., Ltd.'s listing application filed with HKEX on 13 February 2026 has lapsed after six months; CICC acted as the original sole sponsor. Both core products have initiated Phase III clinical trials in China: VVN461 (high dose), a novel JAK1/TYK2 dual-target inhibitor for non-infectious anterior uveitis, and VVN001, a second-generation LFA-1 antagonist for dry eye disease; the Company plans to submit an IND amendment in Q2 2026 and initiate VVN461 (high dose) Phase III in the US by the end of 2026.
NewTimeSpace News: Hunan Junxin Environmental Protection Co., Ltd.'s listing application filed with HKEX on 13 February 2026 has lapsed after six months; CICC and CITIC Securities acted as the original joint sponsors. Ranked by average grid-connected electricity per tonne of waste, the Company ranked first among all waste-to-energy enterprises in China in 2024, operating the Changsha Environmental Protection Industrial Park with a daily treatment capacity of 10,600 tonnes, and has expanded into Central Asian markets including Kyrgyzstan and Kazakhstan.
NewTimeSpace News: ProteLight Pharmaceuticals (Jiangsu) Co., Ltd.'s listing application filed with HKEX on 13 February 2026 has lapsed after six months; CITIC Securities acted as the original sole sponsor. Core product PL-5 (Peceleganan) is the world's first ganan-class drug to have a new drug application submitted, developed under the membrane discrimination mechanism theory, with the NDA submitted in China in 2024 and a Phase II trial ongoing in the US; the Company had nine candidates across four therapeutic areas as of the latest practicable date.
NewTimeSpace News: Shenzhen Immunofoco Biotechnology Co., Ltd.'s listing application filed with HKEX on 13 February 2026 has lapsed after six months; Huatai International acted as the original sole sponsor. Core product IMC002, a potentially best-in-class anti-CLDN18.2 CAR-T cell therapy candidate ranking second globally in clinical progress, is in pivotal Phase III; the global CAR-T cell therapy market is expected to grow from USD 4.7 billion in 2024 to USD 35.2 billion in 2035.
NewTimeSpace News: Shenzhen Hai Robotics Innovation Intelligent Technology Group Co., Ltd.'s listing application filed with HKEX on 13 February 2026 has lapsed after six months; Goldman Sachs and CITIC Securities acted as the original joint sponsors. According to CIC, in 2024 the Company was the world's largest provider of ACR (automated case-handling robot) solutions, with a market share of over 30% by revenue and shipment volume, covering more than 40 countries and regions; orders from markets outside mainland China accounted for over 50% for the nine months ended 30 September 2025.
NewTimeSpace News: Nanjing Novlead Biotechnology Co., Ltd. filed with HKEX on 13 February 2026 with CCB International as sole sponsor, which lapsed after six months. The Company is the world's only enterprise covering a complete product line across NO therapeutic and diagnostic applications; core product iNOwill is the world's first electrochemical catalytic iNO therapy device (No. 1 by market share in China's iNO therapy market in 2024), with 5 approved products and 4 pipeline candidates.
NewTimeSpace News: On 12 August 2026, ZELGEN (688266.SH) filed its second listing application with HKEX, with CICC as sole sponsor. The Company has four marketed drugs and 10 candidates across 29 major clinical programmes, with ZG006 being the world's first DLL3/DLL3/CD3 trispecific antibody. Financially, the Company recorded aggregate net losses of approximately RMB 611 million in 2023-2025 and turned to a net profit of RMB 640 million in H1 2026 driven by the AbbVie upfront payment, while cautioning that the profitability may not be sustainable in the near term.
NewTimeSpace News: On 12 February 2026, Salubris (002294.SZ) submitted a listing application to the Hong Kong Stock Exchange, which lapsed after six months, with Goldman Sachs, Citi and CITIC Securities as sole sponsors; the company ranked second by revenue among China's cardiovascular innovative drug companies in 2024 and holds the second-largest CKM innovative drug pipeline among domestic companies, with innovative drug revenue share rising from 30.1% in 2023 to 37.7% in 2024 and further to 51.6% for the first nine months of 2025.
NewTimeSpace News: On 11 August 2026, Hangzhou CIEC Group Co., Ltd. re-submitted a listing application to the HKEX Main Board, with CICC as the sole sponsor; as a commodity industry service provider and trader, the Company ranks fifth in China by 2025 trade volume and sales revenue, second in steel exports and second in iron ore trade volume, with operations covering more than 80 countries and regions.
Newtimespace News: Beijing Kunlun Tech Co., Ltd. (300418.SZ) announced its plan to issue overseas-listed foreign capital shares (H-shares) and list on the Main Board of The Stock Exchange of Hong Kong Limited. The Company held the 2nd meeting of the 6th Board of Directors on 10 August 2026 and approved relevant proposals. The proposed offering is still subject to shareholders’ approval and regulatory consents from authorities including the China Securities Regulatory Commission and HKEX.
NewTimeSpace News: The listing application of Sieyuan Electric Co., Ltd. submitted to the HKEX on 11 February 2026 has lapsed, as it has been pending for six months, with CITIC SEC having served as the original sole sponsor. According to Frost & Sullivan, by 2024 revenue in China's power transmission, distribution and control equipment market, the Company ranked eighth among international enterprises, fifth among domestic enterprises and third among domestic private enterprises, with a market share of 3.5%. Its business has covered more than 100 countries and regions worldwide.
